EP Wealth Advisors LLC Makes New $240,000 Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

EP Wealth Advisors LLC purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,693 shares of the company’s stock, valued at approximately $240,000.

Several other large investors also recently modified their holdings of NRIX. Amalgamated Bank raised its stake in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after buying an additional 559 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the last quarter. ClariVest Asset Management LLC increased its position in shares of Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after acquiring an additional 1,766 shares in the last quarter. Finally, Quarry LP raised its holdings in shares of Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after acquiring an additional 2,435 shares during the last quarter.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the sale, the insider now owns 24,592 shares in the company, valued at $614,800. This represents a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,401 shares of company stock valued at $437,453. Company insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Oppenheimer increased their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective on the stock. Royal Bank of Canada reduced their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. HC Wainwright boosted their price target on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.35.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $20.27 on Friday. The firm has a market cap of $1.44 billion, a PE ratio of -6.97 and a beta of 2.11. Nurix Therapeutics, Inc. has a 1 year low of $7.65 and a 1 year high of $29.56. The stock’s fifty day moving average price is $23.64 and its two-hundred day moving average price is $22.17.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). The business had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.